These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

892 related items for PubMed ID: 34397684

  • 1. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
    Duan XY, Liu SY, Yin DG.
    Medicine (Baltimore); 2021 Jul 30; 100(30):e26431. PubMed ID: 34397684
    [Abstract] [Full Text] [Related]

  • 2. Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs.
    Qiu M, Ding LL, Zhou HR.
    Am J Cardiovasc Drugs; 2022 Jan 30; 22(1):69-81. PubMed ID: 34231123
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials.
    Wei XB, Wei W, Ding LL, Liu SY.
    Prim Care Diabetes; 2021 Apr 30; 15(2):208-211. PubMed ID: 32912710
    [Abstract] [Full Text] [Related]

  • 4. Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis.
    Qiu M, Ding LL, Wei XB, Liu SY, Zhou HR.
    J Cardiovasc Pharmacol; 2021 Jan 01; 77(1):34-37. PubMed ID: 33136765
    [Abstract] [Full Text] [Related]

  • 5. Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis.
    Li X, Wu H, Peng H, Jiang H.
    Front Endocrinol (Lausanne); 2022 Jan 01; 13():1078686. PubMed ID: 36589800
    [Abstract] [Full Text] [Related]

  • 6. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
    Kongmalai T, Hadnorntun P, Leelahavarong P, Kongmalai P, Srinonprasert V, Chirakarnjanakorn S, Chaikledkaew U, McKay G, Attia J, Thakkinstian A.
    Front Endocrinol (Lausanne); 2023 Jan 01; 14():1216160. PubMed ID: 38179304
    [Abstract] [Full Text] [Related]

  • 7. Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis.
    Qiu M, Ding L, Zhou H.
    Medicine (Baltimore); 2021 Mar 12; 100(10):e25121. PubMed ID: 33725910
    [Abstract] [Full Text] [Related]

  • 8. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
    Giugliano D, Longo M, Signoriello S, Maiorino MI, Solerte B, Chiodini P, Esposito K.
    Cardiovasc Diabetol; 2022 Mar 16; 21(1):42. PubMed ID: 35296336
    [Abstract] [Full Text] [Related]

  • 9. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis.
    Diallo A, Carlos-Bolumbu M, Galtier F.
    Acta Diabetol; 2023 Dec 16; 60(12):1651-1662. PubMed ID: 37439858
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX, Liang S, Gao L, Liu H.
    PLoS One; 2021 Dec 16; 16(2):e0244689. PubMed ID: 33606705
    [Abstract] [Full Text] [Related]

  • 11. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
    Zhang Y, Jiang L, Wang J, Wang T, Chien C, Huang W, Fu X, Xiao Y, Fu Q, Wang S, Zhao J.
    Cardiovasc Diabetol; 2022 Nov 05; 21(1):232. PubMed ID: 36335326
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis.
    Tian L, Ai S, Zheng H, Yang H, Zhou M, Tang J, Liu W, Zhao W, Wang Y.
    Front Pharmacol; 2022 Nov 05; 13():986186. PubMed ID: 36506550
    [Abstract] [Full Text] [Related]

  • 13. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis.
    Chen JY, Pan HC, Shiao CC, Chuang MH, See CY, Yeh TH, Yang Y, Chu WK, Wu VC.
    Cardiovasc Diabetol; 2023 Oct 27; 22(1):290. PubMed ID: 37891550
    [Abstract] [Full Text] [Related]

  • 14. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S.
    Adv Ther; 2022 Feb 27; 39(2):845-861. PubMed ID: 34881413
    [Abstract] [Full Text] [Related]

  • 15. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Patorno E, Htoo PT, Glynn RJ, Schneeweiss S, Wexler DJ, Pawar A, Bessette LG, Chin K, Everett BM, Kim SC.
    Ann Intern Med; 2021 Nov 27; 174(11):1528-1541. PubMed ID: 34570599
    [Abstract] [Full Text] [Related]

  • 16. Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods.
    Chen HB, Yang YL, Meng RS, Liu XW.
    ESC Heart Fail; 2023 Apr 27; 10(2):1231-1241. PubMed ID: 36702979
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ.
    Circ Res; 2018 May 11; 122(10):1439-1459. PubMed ID: 29748368
    [Abstract] [Full Text] [Related]

  • 18. The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.
    Ueda P, Wintzell V, Dahlqwist E, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Melbye M, Hviid A, Svanström H, Pasternak B.
    Diabetes Obes Metab; 2022 Mar 11; 24(3):473-485. PubMed ID: 34738703
    [Abstract] [Full Text] [Related]

  • 19. Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases: A meta-analysis of cardiovascular outcome trials.
    Zhao LM, Huang JN, Qiu M, Ding LL, Zhan ZL, Ning J.
    Medicine (Baltimore); 2021 Oct 01; 100(39):e27362. PubMed ID: 34596148
    [Abstract] [Full Text] [Related]

  • 20. Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.
    Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Schmedt N, Koeneman L, Déruaz-Luyet A, Paik JM, Patorno E.
    Cardiovasc Diabetol; 2024 Feb 08; 23(1):57. PubMed ID: 38331813
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.